Navigation Links
Sentinel Oncology add ADME From O2h to Their New Extended Contract
Date:10/25/2010

Sentinel Oncology add ADME From O2h to Their New Extended Contract -- CAMBRIDGE, England, October 25, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Joint Ventures Click to view news release full screen  

Sentinel Oncology add ADME From O2h to Their New Extended Contract

 

CAMBRIDGE, England, October 25, 2010 /PRNewswire/ -- Executives from Sentinel Oncology Limited (Cambridge,UK) signed an agreement with O2h (Ahmedabad, India) to extend the number of FTEs working for Sentinel Oncology. Under this new contract, O2h will also provide ADME services to Sentinel Oncology.

Bob Boyle, CEO of Sentinel Oncology said that he appreciated O2h's continual support and it being a reliable chemistry partner, providing flexible multi-FTE chemistry support to the company.

COO of Sentinel Oncology, Stuart Travers said "ADME support added onto the chemistry FTEs provides us with a seamless and quick way of gathering data for our on-going projects. We look forward to working with O2h and of taking advantage of its expanding ADME portfolio."

Sunil Shah, CEO, O2h "We have an incredibly good relationship with Sentinel Oncology and are happy to continue supporting their virtual model with not just our chemistry but also ADME. O2h ADME services are being expanded with current purchase of high-spec specialised instruments and support of our long-standing clients is appreciated."

About Oxygen Healthcare Ltd

O2h is a 5 year old discovery services company co-located in Cambridge, UK and Ahmedabad, India. The Indian operations provide a high level of chemistry expertise while UK office provides project management support. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services lab-units and ADME. Further information on O2h can be found at http://www.o2h.com.

About Sentinel Oncology Limited

Sentinel Oncology was founded at the beginning of 2005 and has built a pipeline of small molecules designed to target the hallmarks of solid tumours. In particular, Sentinel Oncology is developing small molecule inhibitors that are activated selectively under tumour Hypoxia (the low oxygen environment found in many solid tumours). Our vision is to develop new drugs for the treatment of cancer that are void of the systemic toxicities often associated with current therapies. Further information on Sentinel Onology can be found at http://www.sentineloncology.com/.


'/>"/>
SOURCE Oxygen Healthcare Ltd (O2h)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform
2. US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials
3. US Oncology to Report 2010 Third Quarter Operating Results
4. Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
5. Dr. Ramin Mirhashemi, MD of Gynecological Oncology Associates Discusses Uterine Fibroid Treatment with da Vinci Robotic Hysterectomy Surgery
6. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
7. Reportlinker Adds Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
8. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
9. Reportlinker Adds Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
10. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
11. OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... BOSTON , Feb. 10, 2016  Matchbook, ... sourcing for fast growing biotech companies, announced today ... Senior Procurement Strategic Advisor. Jim brings nearly 25 ... sourcing and procurement, having spent nearly two decades ... Supply Chain/Logistics and Procurement at Genzyme and, most ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor ... expecting to fill more than 100 tables for its annual event, which will ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC reports ... program, Sonalink™ remote monitoring. The inaugural launch of this new technology occurred over ... Dr. Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. ...
(Date:2/10/2016)... ... February 10, 2016 , ... Curoverse announced today that the ... provides capabilities for managing and processing genomic and health data at petabyte scale. ... collecting and analyzing genomic data,” said Adam Berrey chief executive officer at Curoverse. ...
Breaking Biology Technology:
(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... the addition of the "Global Facial ... offering. --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has ... Facial Recognition Market 2016-2020" report to ... Markets ( http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ...
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... fourth quarter of 2014. Gross margin was 46% (32). ... Earnings per share increased to SEK 6.39 (loss: 0.49). Cash ... --> --> January to December ... 1,142% compared with 2014. Gross margin was 43% (31). ...
(Date:2/3/2016)... , Feb. 3, 2016 Vigilant Solutions announces ... Department in Missouri solved two ... reader (LPR) data from Vigilant Solutions. Brian ... in which the victim was walking out of a convenience store and witnessed ... next to his vehicle, striking his vehicle and leaving ...
Breaking Biology News(10 mins):